10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Employees

1,306

Sector

Medical Equipment, Supplies & Distribution

Calendar

Feb. 17 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-08	17.47 $	-1.69%	1,373,444
25-12-05	17.77 $	-2.09%	1,913,587
25-12-04	18.15 $	+1.57%	1,826,659
25-12-03	17.87 $	-0.39%	1,716,467
25-12-02	17.94 $	-0.77%	1,853,162

Delayed Quote Nasdaq, December 08, 2025 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

17.47USD

Average target price

16.57USD

Spread / Average Target

-5.14%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-08 pm EST			5-day change	1st Jan Change
17.47 ^USD	-1.69%		-3.37%	+21.66%

Dec. 02	Morgan Stanley Downgrades 10x Genomics to Equalweight From Overweight, Lifts Price Target to $20 From $17	MT
Nov. 25	10x Genomics Insider Sold Shares Worth $251,936, According to a Recent SEC Filing	MT

Capitalization	2.21B 1.9B 1.79B 1.66B 3.06B 199B 3.34B 20.82B 8.06B 94.11B 8.3B 8.12B 345B	P/E ratio 2025 *	-33.4x	P/E ratio 2026 *	-18.5x
Enterprise value	1.77B 1.53B 1.43B 1.33B 2.45B 160B 2.68B 16.68B 6.46B 75.41B 6.65B 6.51B 276B	EV / Sales 2025 *	2.8x	EV / Sales 2026 *	2.85x
Free-Float	85.02%	Yield 2025 *	-	Yield 2026 *	-

Dec. 02	Morgan Stanley Downgrades 10x Genomics to Equalweight From Overweight, Lifts Price Target to $20 From $17	MT
Nov. 25	10x Genomics Insider Sold Shares Worth $251,936, According to a Recent SEC Filing	MT
Nov. 18	New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium	CI
Nov. 14	10x Genomics, Inc. Announces Executive Changes, Effective January 1, 2026	CI
Nov. 07	UBS Adjusts Price Target on 10x Genomics to $14 From $13, Maintains Neutral Rating	MT
Nov. 26	10x Genomics, Inc., Q3 2025 Earnings Call, Nov 06, 2025
Nov. 06	10X Genomics Q3 revenue beats expectations, net loss narrows	RE
Nov. 06	(TXG) 10x Genomics, Inc. Expects Q4 Revenue Range $154.0M - $158.0M	MT
Nov. 06	Earnings Flash (TXG) 10x Genomics, Inc. Reports Q3 Revenue $149.0M, vs. FactSet Est of $142.5M	MT
Nov. 06	10X Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2025	CI
Nov. 06	10x Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Oct. 29	10X Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research	CI
Oct. 20	10x Genomics & Anthropic partner to make single cell & spatial analysis more accessible	RE

Dec. 02	Morgan Stanley Downgrades 10x Genomics to Equalweight From Overweight, Lifts Price Target to $20 From $17	MT
Nov. 07	UBS Adjusts Price Target on 10x Genomics to $14 From $13, Maintains Neutral Rating	MT
Nov. 06	10X Genomics Q3 revenue beats expectations, net loss narrows	RE
Oct. 20	BofA Adjusts Price Target on 10x Genomics to $13 From $15	MT
Sep. 11	Piper Sandler Initiates 10x Genomics at Neutral With $15 Price Target	MT

10x Genomics, Inc. Stock

Equities

TXG

US88025U1097

Medical Equipment, Supplies & Distribution

Valuation: 10x Genomics, Inc.

Chart: 10x Genomics, Inc.

Latest news: 10x Genomics, Inc.

Last Transcript: 10x Genomics, Inc.

Analysts' recommendations: 10x Genomics, Inc.

Press Releases: 10x Genomics, Inc.

News in other languages: 10x Genomics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: 10x Genomics, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Nov. 19	New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics Xenium	AQ
Nov. 18	New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium	PR
Nov. 11	10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025	PR
Nov. 06	10x Genomics : Third Quarter 2025 Prepared Remarks	PU
Nov. 06	10x Genomics: Q3 Earnings Snapshot	AQ

24-08-09	RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...
24-07-23	RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU. : CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...
24-07-16	RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Dollar Tree, JPMorgan, Broadcom, Chipotle, Burberry...
21-05-17	Cathie Wood, nouvelle popstar de l’investissement ?
21-05-07	PUMP / DUMP #10

1 day	-1.69%
1 week	-3.37%
Current month	-7.12%
1 month	+14.56%
3 months	+25.41%
6 months	+85.46%
Current year	+21.66%

1 week	17.06	18.51
1 month	15.12	20.34
Current year	6.78	20.34
1 year	6.78	20.34
3 years	6.78	63.57
5 years	6.78	208.99
10 years	6.78	208.99

Manager	Title	Age	Since
Serge Saxonov CEO	Chief Executive Officer	48	2012-07-01
Ben Hindson PSD	President	50	2012-09-30
Adam Taich DFI	Director of Finance/CFO	50	2024-08-11

Director	Title	Age	Since
Ben Hindson BRD	Director/Board Member	50	2012-07-01
Serge Saxonov BRD	Director/Board Member	48	2012-07-01
John Stuelpnagel CHM	Chairman	67	2013-07-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
10X GENOMICS, INC.	-1.69%	-3.37%	+10.08%	-52.46%	2.21B
BIOMÉRIEUX	0.00%	-3.16%	+6.21%	+7.57%	14.31B
GUARDANT HEALTH, INC.	+2.11%	-1.00%	+182.53%	+120.00%	13.42B
CARIS LIFE SCIENCES, INC.	-1.73%	+8.87%	-	-	8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-1.09%	-0.77%	-14.29%	+27.49%	6.58B
LANTHEUS HOLDINGS, INC.	-1.63%	+5.40%	-30.05%	+16.37%	4.13B
DIASORIN S.P.A.	-0.36%	+0.26%	-40.83%	-53.05%	3.87B
AUTOBIO DIAGNOSTICS CO., LTD.	-0.47%	-1.48%	-21.17%	-40.04%	2.91B
ANDON HEALTH CO., LTD.	-0.47%	-2.02%	-4.98%	-30.27%	2.41B
BEIJING HOTGEN BIOTECH CO., LTD.	+4.89%	+3.43%	+189.23%	+105.71%	2.27B
Average	-0.06%	+0.75%	+30.75%	+11.26%	6.01B
Weighted average by Cap.	+0.06%	+0.37%	+48.78%	+32.57%

	2025 *	2026 *
Net sales	633M 545M 511M 475M 876M 57.05B 956M 5.96B 2.31B 26.93B 2.37B 2.32B 98.68B	611M 526M 493M 459M 845M 55.05B 922M 5.75B 2.23B 25.99B 2.29B 2.24B 95.22B
Net income	-70.35M -60.56M -56.85M -52.85M -97.41M -6.34B -106M -662M -257M -2.99B -264M -258M -10.97B	-116M -99.92M -93.8M -87.2M -161M -10.46B -175M -1.09B -423M -4.94B -436M -426M -18.1B
Net Debt	-439M -378M -355M -330M -608M -39.59B -663M -4.13B -1.6B -18.69B -1.65B -1.61B -68.48B	-472M -406M -381M -354M -653M -42.54B -713M -4.44B -1.72B -20.09B -1.77B -1.73B -73.59B